HC Wainwright Analysts Reduce Earnings Estimates for EYPT

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Investment analysts at HC Wainwright decreased their Q1 2025 earnings estimates for EyePoint Pharmaceuticals in a report issued on Thursday, March 6th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.63) per share for the quarter, down from their prior estimate of ($0.44). HC Wainwright currently has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals' Q2 2025 earnings at ($0.63) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($2.81) EPS.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%.

EYPT has been the topic of several other research reports. Citigroup started coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Chardan Capital reissued a "buy" rating and set a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $26.63.

Remove Ads

EyePoint Pharmaceuticals Stock Down 5.6 %

EyePoint Pharmaceuticals stock traded down $0.41 during midday trading on Monday, reaching $6.92. The company's stock had a trading volume of 304,130 shares, compared to its average volume of 835,008. The company has a market cap of $475.67 million, a P/E ratio of -3.46 and a beta of 1.41. The business has a 50-day simple moving average of $7.25 and a 200-day simple moving average of $8.42. EyePoint Pharmaceuticals has a fifty-two week low of $5.54 and a fifty-two week high of $23.97.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of EYPT. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of EyePoint Pharmaceuticals by 31.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 90,349 shares of the company's stock worth $673,000 after buying an additional 21,719 shares during the period. Woodline Partners LP raised its stake in EyePoint Pharmaceuticals by 25.4% during the 4th quarter. Woodline Partners LP now owns 501,724 shares of the company's stock valued at $3,738,000 after acquiring an additional 101,724 shares during the last quarter. Squarepoint Ops LLC lifted its position in EyePoint Pharmaceuticals by 83.3% during the 4th quarter. Squarepoint Ops LLC now owns 40,514 shares of the company's stock worth $302,000 after acquiring an additional 18,416 shares during the period. Stempoint Capital LP purchased a new position in shares of EyePoint Pharmaceuticals in the 4th quarter valued at approximately $4,317,000. Finally, Suvretta Capital Management LLC increased its holdings in shares of EyePoint Pharmaceuticals by 31.1% in the fourth quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company's stock valued at $50,534,000 after purchasing an additional 1,607,268 shares during the period. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.